相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia The PEONY Phase 3 Randomized Clinical Trial
Zhimin Shao et al.
JAMA ONCOLOGY (2020)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gunter von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
HER2-directed therapy: current treatment options for HER2-positive breast cancer
Shahid Ahmed et al.
BREAST CANCER (2015)
Comparative Effectiveness of Neoadjuvant Therapy for HER2-Positive Breast Cancer: A Network Meta-Analysis
Aiko Nagayama et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Evandro de Azambuja et al.
LANCET ONCOLOGY (2014)
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
Andre Robidoux et al.
LANCET ONCOLOGY (2013)
Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer
Steven A. Limentani et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
HD Bear et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors
V Guarneri et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer:: results of a multicenter phase II trial
BP Coudert et al.
ANNALS OF ONCOLOGY (2006)